reason report
mona lisa smile initi ipha outperform
bottom line initi coverag innat pharma ipha
outperform op rate price target innat
built deep understand innat immun twenti year
found compani robust pipelin one market
three clinic sever preclin asset signific part
valuat come two hematolog program rel low
risk lumox moxetumomab pasudotox-tdfk
advanc innat immun program monalizumab licens
astrazeneca azn cover though program enter phase
next year assum early-phas risk given view
efficaci signal strong enough support progress phase
astrazeneca innat share cohort expans data revisit
decis also see potenti addit upsid innat take
preclin program forward notabl tri-specif nk engag
investor expect take-out innat view
compani tie multi-facet collabor
astrazeneca sanofi sni cover also expect
astrazeneca acquisit innat product discoveri engin
astrazeneca could destroy acquisit
like innat decis acquir lumox build small
commerci organ focus commerci effort rare
hematolog indic allow build target commerci
medic franchis build capabl infrastructur well
support develop
earli data cutan t-cell lymphoma ctcl
excit compani posit acceler approv
sezari syndrom ipha previous report object respons
rate orr ctcl patient sezari syndrom
ss patient expect efficaci data
investor larg pessimist second-gener
checkpoint inhibitor like monalizumab lack
singl agent activ histor failur innat lirilumab anti-
may temper investor enthusiasm monalizumab
think earli efficaci signal monalizumab
plu cetuximab anti-egfr squamou cell carcinoma head
neck scchn monalizumab plu imfinzi durvalumab colorect
cancer promis though neither met bar proof-
compel first-in-class checkpoint inhibitor target
nk- t-cell reliev suppress human leukocyt hla-e
tumor cell addit cohort expans data late earli
shift monalizumab risk profil may provid inform
better enrich patient benefit
blend dcf loe
multipl peak sale dr
net debt total capit
year price history/av daili volume mil ipha
compani inform svb leerink llc research
revenu ep ifr
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
mona lisa smile initi ipha outperform price target
overview ipha
valuat risk
ipha commerci stage biotech compani focus develop commerci first-
in-class therapeut antibodi oncolog indic signific unmet medic need
found
lumox hairi cell leukemia
fda approv commerci
list
monalizumab
develop
scchn solid tumor t-cell leukemia
trial
solid tumor nsclc
seven preclin asset two expect
enter clinic
timelin key near-term catalyst
eu regulatori file lumox
ipha us commerci launch lumox
long term follow-up data lumox
initi monalizumab cetuximab
scchn
expans cohort data monalizumab
cetuximab scchn
invest thesi valuat risk
low-risk revenu approv lumox hairi cell leukemia
high probabl acceler approv cell lymphoma
larg develop program first-in-class nk- t- cell therapi monalizumab includ
phase trial combin cetuximab start
product discoveri engin sever compel pre-clin program includ tri-specif nk-
engag antagonist adenosin pathway
leader biolog inquiri innat immun
innat reli partner develop commerci capabl infrastructur
valuat price target base blend dcf multiples-bas analysi
simul revenu anticip loss exclus innat pharma oncolog program use
discount rate account net cash project revenu gener rang
outcom innat pharma oncolog asset deriv mont carlo simul entir
monalizumab single-ag activ signal combin met bar
proof concept
fail replic earli clinic signal tellomak studi
innat nascent commerci organ fail maxim lumox sale
unlik acquisit target due tie-up astrazeneca sanofi
innat valu balanc across multipl asset span
develop cycl
nol
nol
note use target-price mileston stare trial monalizumab cetuximab scchn reflect cash
ionian immuno-oncolog industri analyt assum overhead result return equal discount rate
innat pharma ipha price target upsid downsid scenario
share price
program
 iph-
use
monalizumab
posit clinic signal
succe combin
cetuximab scchn
subpar clinic efficaci
number monalizumab iph-
plu
preclin program
enter clinic
base
revenu multipl appli
simul sale proxi
data ctcl
tellomak trial
oct launch
list
innat pharma ipha part valuat
revenu multipl product base us peak sale lumox peak sale us eu adjust ownership share discount back
compani report svb leerink estim
import near-term catalyst innat expans cohort
monalizumab plu cetuximab scchn
open-label singl arm studi
open-label cetuximab io
pretreat r/m scchn line prior
open-label cetuximab anti-
io naiv r/m scchn prior
open-label durvalumab
trial pivot
open-label gemcitabin
nsclc
single-arm durvalumab
single-arm nivolumab
ipha pipelin near-term catalyst aim demonstr
potenti innat immun system target platform
updat mf/ptcl efficaci
follow prelim data
safeti data exp cohort
adapt fill
innat asset score middl pack level biolog evid
clinic signal io asset coverag univers
score mechan part
survey
base pre-clin data innat
promis asset earli
nk-cell engag well
expect asset move toward
right get clinic evid
single-ag combin
sourc svb leerink io team judgement base review literatur compani present svb leerink proprietari survey medacorp immunologist immuno-oncologist februari
ipha extens partnership astrazeneca azn
commerci lumox licens ipha azn
develop monalizumab
preclin nkce
mileston payment upon commenc phase monalizumab
conting payment potenti licens agreement azn well sanofi
nk-cell integr part
innat immun
nk-cell directli recogn kill cancer cell cycl tightli
intertwin t-cell adapt immun
chemokin recruit
dc cell tme
mab
cytokin
releas tumor antigen
nk-cell numer activ inhibitor receptor
antigen-independ nearli target therapeut intervent
select activ inhibitori interact
nk-cell numer activ inhibitori receptor antigen-independ
except recogn antigen bound monoclon antibodi
signal nk-cell come directli infect tumor cell stress ligand like
mica and/or antigen-pres cell present dendrit cell
express receptor highli variabl person-to-person within singl person
express pattern phenotyp combin educ achiev bind
ligand normal self cell defin specif nk-cell function
comprehens list nk-cell therapeut approach see guillerey et al chiosson et al
net balanc activ inhibitori absenc inhibitori signal
regul nk-cell attacksever signatur common tumor recognit
stimul
must also
absenc inhibitori
inhibitori signal
requir strong
adcc efficaci well valid monoclon antibodi higher affin
fcriiia associ better respons
clinic efficaci monoclon antibodi mab fc receptor bind
trastuzumab cetuximab mediat bind nk-cell macrophag
polymorph high affin fcriiia variant indic patient
variant v/v better clinic outcom patient low affin variant f/f
antibodi includ rituximab trastuzumab cetuximab
therapeut success fc optim mab benefit margetuximab op
jonathan chang patient low affin variant
much like t-cell target therapi immunosuppress tumor micro-
environ tme may present barrier nk-cell targeted-therapi
employ tumor
activ especi solid tumor
mani immunomodulatori molecul
suppress t-cell also suppress nk-cell
adenosin tgf numer agent
clinic address
mask receptor nk-cell
nk-cell easili exhaust limit persist
histor led subpar therapeut efficaci
heterogen patient nk-cell substrat
patient may benefit therapi target
expert believ nk-cell innat lymphoid
cell broadli also immunosuppress
therapi may inadvert stimul function
includ sever target adenosin pathway ipha azn op geoffrey porg nv crv iteo op jonathan chang other
tgf mrk-etr/gsk other
theme rememb consid nk-cell direct therapi
multifunctionalnk-cel surveil recogn kill cancer cell directli also
prime activ regul adapt immun
heterogeneousther numer nk-cell subpopul uniqu
phenotyp function potenti treat cancer
polymorphichuman genom variat result larg differ nk-cell
cytotox like respons nk-cell target therapi genet
enrich may requir
validatedclear contribut nk-cell mediat adcc monoclon antibodi
first-in-class checkpointwil
hla-e dampen innat adapt immun respons tumor
overexpress correl poor respons
nk-cell activ regul
hla-e interact
co-express
t-cell
hla-e express solid
mm patient high hla-e
wors outcom
molecul complex interact
bind hetero-dim
known self-recognit
though lower-affin depend
specif peptid present
hla-e bind heterodim
express evid
bind hla-e also result
dampen signal cell
tumor seem evad immun kill
hla-e like express
hla-e express associ
poor clinic outcom variou solid
tumor type multipl myeloma
present mm unpublish note hla-e like classic hla present peptid mostli deriv leader sequenc classic hla
monalizumab first-in-class checkpoint inhibitor target hla-e bind
receptor nk cell
monalizumab enhanc nk-cell mediat adcc tumor cell kill vitro
monalizumab synergist activ two murin tumor model express
mous equival hla-e though specif vari
one model monalizumab single-ag activ activ combin
depend nk cell
model rma monalizumab single-ag activ activ
combin depend cell
mice express cell look earli adapt resist mechan
stimul cell
improv efficaci vaccin nk-cell depend
express correl cell checkpoint model anti-
fail improv efficaci vaccin
andr et al cell van montfoort et al cell van et al journal immunotherapi cancer innat poster van
similar mice find clinic across two trial set
monalizumab shown single-ag activ
monalizumab dose escal gynecolog
cancer stabl diseas object
monalizumab single-ag cohort part
upstream trial
earli clinic data monalizumab cetuximab gave interest
signal need addit data untangl contribution-of-part
combin monalizumab cetuximab
previous treat scchn show impress
overal respons rate orr
compar favor approv singl agent
combin ppt respons
cetuximab put interest data
set see appendix threshold
combin interest signal io-nav
orr pretreat orr patient
evalu expans cohort
two three
r/m scchn numberorr cr shrinkag mdor mo mo mo os monalizumab navemonalizumab pretreatedmonalizumab note mix popul line line line relaps metatstat r/m report nr evalu ne clinic develop plan monalizumab plu cetuximab scchn
pivot phase trial start
data present
updat data present esmo
ipha expect present preliminari efficaci data next month
io-pretr second expans cohort
io-nav third expans cohort
first monalizumab random phase trial start combin cetuximab
scchn assum typic phase time probabl see data
though believ initi signal strong enough move directli random phase
suspect astrazeneca made go-forward decis see data cohort
ipha receiv mileston payment upon first patient dose combin
intrigu earli evid monalizumab
durvalumab benefit difficult set
mss-crc typic non-respons
intrigu activ mss-crc major
treat least three
prior line therapi
case stabl diseas
evalu patient orr
though orr impress given
difficult settingstivarga lonsurf
approv r/r respons
rate forward
signal would riski
phase trial on-going combo
monalizumab durvalumab nsclc
scchn
earli clinic data esmo monalizumab durvalumab
folfox bevacizumab mss under-perform benchmark
chang tumor size mona durva folfox bev
mss numberorr cr shrinkag mdor mo mpf mo mo mo mona durva folfox bevacizumab folfox fp fp note size respons on-going follow-up find present braf wild-typ patient fluoropyrimidin fp microsatellit stabl mss colorect cancer reach nr maxim clinic respons may requir patient enrich base tumor
though initi trial enrich specif patient subtyp sever
biomark may enrich respons expect innat azn explor
high express hla-e tumor
patient genet polymorph result educ cell may
cytotox signal block
express infiltr cell til preexist cell immun
patient without underli cmv infect may make nk cell activ
instead inhibit hla-e activ receptor
note cytomegaloviru cmv infect lead select expans nk cell popul kol note express mutual exclus
medacorp kol discuss van et al journal immunotherapi cancer
multipl compet approach amplifi benefit monoclon
antibodi innat focus heme malign
prevent tumor inhibit nk-cell
increas number toxic nk-cell use
prevent tumor inhibit phagocytosi use
eat signal sirp
nk cell engin high-affin non-
note cytomegaloviru cmv infect lead select expans nk cell popul kol note express mutual exclus
medacorp kol discuss van et al journal immunotherapi cancer
on-going trial catalyst monalizumab
scchn line
prior therapi
preliminari data report
esmo
escal
orr esmo
report
nsclc progress
ccrt
first-in-class de-risk
asset innat pipelin
express t-cell lymphoma cell kill tumor cell adcc
consist express
subtyp cutan t-cell
greatest express szari
syndrom ss transform
also high unmet medic
antigen tumor cell recruit
nk-cell lyse tumor via
adcc typic mechan
cell lysi
compar alemtuzumab
propos mechan
mediat effici kill primari szari
cell ex vivo increas anim surviv xenograft model
earli clinic data cutan t-cell lymphoma ctcl
excit signal think like make market
ctcl patient previous
least two prior line therapi show
impress overal respons rate orr
analysi ss patient without larg
cell transform lct increas orr
well toler dose limit
toxic maxim toler dose
reach patient stop treatment due
fda grant track design jan
initi may
r/r ctcl numberorr cr mswat mdor mo mpf mo syndrom ss without moga note overal respons asses use global composit respons score base respons skin blood lymph node viscera requir infilitr mononculear cell express skin phenotyp aberr cicul t-cell express modifi sever weight asses tool mswat larg cell transform lct mogalizumab moga global orr ss patient compart tellomak phase studi posit potenti rapid
approv ss well explor sever addit clinic hypothes
believ clinic strategi evalu mogamulizumab moga kirin hold
may facilit quick regulatori approv leverag ipha commerci infrastructur
result dedic ss cohort may support futur bla file fda
follow approv ss may move earlier line compet moga market share
could annual revenu opportun ionian simul
preliminari efficaci data expect next month
efficaci data post moga
outcom singl agent mycosi fungoid data present expect
outcom plu chemotherapi data present expect
bring complement io
biolog rational target receptor
propos mechan
axi particip
microenviron recruit
infiltr myeloid deriv
inhibit axi use anti-
immun cell infiltr function
express mdsc
also express varieti cell
includ macrophag dendrit
cellswhich could result unexpect
result clinic
blockad use l-apatm
increas mous surviv
display addit effect combin
antibodi
highli express sever
combin blockad anti-
level elev
initi clinic studi ipha treat patient
combo w/ durvalumab make earli result difficult interpret
result report esmo durvalumab solid tumor difficult interpret
orr small patient number across four cancer type nsclc rcc uc interest
need see greater patient number matur de-risk combin
azn decid evalu combin three expans cohort nsclc io-pretr
requir secondari resist therapi io-nav io-pretr
note io-pretr expans cohort plan phase oct massard et al esmo
cornerston innat t-cell lymphoma
ipha nucleat commerci organ around lumox
agre lumox ideal product build commerci capabl given small size us rep
us msl overlap target physician clinic program
numer excit preclin asset pois
enter clinic
ipha develop next tri-specif gener nk-cell engag
nkce target activ receptor
genentech dragonfli
gt biopharma develop nk-cell engag
enhanc immun cell activ tumor kill
receptor known mitig adcc gt
biopharma dragonfli
ipha platform tri-specif bind two
activ nk-cell receptor
tumor antigen facilit nk-cell tumor lysi
target theoret increas
number nk cell engag recruit
activating-receptor constitut
express
target undisclos preclin experi
use egfr target tumor
tri-specif engag develop part
sanofi two nkce
develop agreement
nkce design mechan innat corpor present
target enzym
adenosin pathway allevi immunosuppress effect adenosin
schemat adenosin pathway involv
synergi
chemotherapi knock-in mice
convers adenosin triphosph atp adenosin promot immunosuppress tumor
microenviron inhibit nk- t-cell receptor
membrane-bound enzym catalyz convers atp adenosin
lead candid bind inhibit membrane-bound
solubl form convert enzym
reduct tme adenosin alon suffici anti-tumor activ anim requir combin
 adcc enabl antibodi chemo tumor reduct
highli competit landscap adenosin target therapeut iteo azn nv
ind partner azn expect respect
note outperform rate geoffrey porg outperform rate jonathan chang innat corpor present
compani file svb leerink equiti research estim
compani file svb leerink equiti research estim
experienc leadership team experi larg pharmaceut
approach mont carlo simul entir immuno-
risk dynam consid
probabl mont carlo simul
probabl technic
probabl disrupt outcom
correl outcom everi
treatment mechanist class
develop path poc trial
probabl technic
note use discount rate compani given simul revenu stream alreadi consid mani risk typic account higher discount rate
object interpret result single-arm combin trial
oncolog inspir riba propos
threshold requir posit early-stag signal
set
ppt orr patient
promis result larger size need verifi
set
activ
set
ppt orr less patient
ppt delta orr patient
ppt delta orr less patient
ppt delta orr
ppt delta orr
proof concept poc fabul signal move aggress registration-en trial
promis intrigu signal confirm signal increas patient number and/or random phase data
disappoint littl evid efficaci project discontinu
also depriorit unaccept toxic pazopanib rcc random os need demonstr combin synergist synergist
sequenc may prefer given toxic expens antoni riba note sourc may requir subscript
iob framework object evalu breakthrough
potenti io pipelin mechan asset
score mechan part
iob object assess
biolog clinic evid
mechan asset
coverag import io
biolog evid io space
increasingli import earli stage
signal combin often
sourc svb leerink io team judgement base review literatur compani present svb leerink proprietari survey medacorp immunologist immuno-oncologist februari
iob evalu criteria evalu single-ag treatment
clariti role cancer immun abil bia activ
desir pleiotropic/context-depend mechan
evid surviv benefit physiologically-relev murin
evid impact absolut immun cell count antigen-
specif activ state prolifer marker vitro kill
potenti immun cell isol anim post dose
specif strength target bind
extend benefit evidenc dot bonu long tail
extent clinic impact standard-of-car bonu long tail
eas identifi respond patient popul base orr
presenc pd marker practic half-lif deliveri
width therapeut window
depend novel un-valid outcom trial design
level unmet medic need given current standard care
criteria asset score
score multipli weight risk score neg impact
given lack random data io score weight non-random data plan shift weight time random data emerg
iob evalu criteria evalu combin treatment
clariti role cancer immun abil bia activ
desir pleiotropic/context-depend mechan
evid surviv benefit physiologically-relev murin
evid impact absolut immun cell count antigen-
specif activ state prolifer marker vitro kill
potenti immun cell isol anim post dose
specif strength target bind
extend benefit evidenc dot bonu long tail
evid dot synergi
extent clinic impact standard-of-car bonu long tail
eas identifi respond patient popul base orr
contribut part
evid synergi base increment orr vs backbon
presenc pd marker practic half-lif deliveri
width therapeut window
depend novel un-valid outcom trial design
level unmet medic need given current standard care
criteria asset score
score multipli weight risk score neg impact
given lack random data io score weight non-random data plan shift weight time random data emerg
durat respons
day therapi
order magnitud
proof concept
probabl technic regulatori success
squamou cell carcinoma head neck
stimul interferon gene
